Second Brazilian pharmaceutical firm signs deal to produce Russia's COVID-19 vaccine

The vaccine still needs Brazil's health regulator (Anvisa) approval to start the production in the second half of November

coronavirus vaccine illustrative image
Photo: Shutterstock
  • In Brazil, four other vaccines are already in trials phase;
  • Paraná’s Tecpar has a deal with RDIF as well.

The Brazilian private pharmaceutical company União Quimica said on Friday it has signed an agreement with the Russian Direct Investment Fund (RDIF) to produce Russia’s Sputnik V vaccine against COVID-19 starting in the second half of November. However, the deal still needs Brazil’s health regulator approval, as reported Reuters.

READ ALSO: Pfizer and BioNTech to produce 2 million COVID-19 vaccines to Ecuador

This is the second initiative to produce Sputnik V vaccine in the country, with Paraná’s Technology Institute, known as Tecpar. In Brazil, four other vaccines are already in trials phase.

Get the best insights about Latin America market in your inbox